These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 18051437)
1. [Rapid identification of subtype-selected agonists of the somatostatin receptor through combinatorial chemistry]. Habashita H Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1810-1. PubMed ID: 18051437 [No Abstract] [Full Text] [Related]
2. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Rohrer SP; Birzin ET; Mosley RT; Berk SC; Hutchins SM; Shen DM; Xiong Y; Hayes EC; Parmar RM; Foor F; Mitra SW; Degrado SJ; Shu M; Klopp JM; Cai SJ; Blake A; Chan WW; Pasternak A; Yang L; Patchett AA; Smith RG; Chapman KT; Schaeffer JM Science; 1998 Oct; 282(5389):737-40. PubMed ID: 9784130 [TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of subtype selective somatostatin receptor agonists. Rohrer SP; Schaeffer JM J Physiol Paris; 2000; 94(3-4):211-5. PubMed ID: 11087999 [TBL] [Abstract][Full Text] [Related]
4. Somatostatin agonists and antagonists--peptide control of growth hormone secretion. Coy DH; Murphy WA; Lance VA; Hocart SJ; Sueiras-Diaz J; Mezo I Adv Exp Med Biol; 1985; 188():325-37. PubMed ID: 2863940 [No Abstract] [Full Text] [Related]
5. Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist. Strowski MZ; Cashen DE; Birzin ET; Yang L; Singh V; Jacks TM; Nowak KW; Rohrer SP; Patchett AA; Smith RG; Schaeffer JM Endocrinology; 2006 Oct; 147(10):4664-73. PubMed ID: 16857751 [TBL] [Abstract][Full Text] [Related]
6. Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues. Coy DH; Meyers C; Arimura A; Schally AV; Redding TW Metabolism; 1978 Sep; 27(9 Suppl 1):1407-10. PubMed ID: 683009 [No Abstract] [Full Text] [Related]
7. Dissociation of somatostatin effects. Peptides inhibiting the release of growth hormone but not glucagon or insulin in rats. Grant N; Clark D; Garsky V; Jaunakais I; McGregor W; Sarantakis D Life Sci; 1976 Sep; 19(5):629-31. PubMed ID: 957897 [No Abstract] [Full Text] [Related]
8. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Yang L; Berk SC; Rohrer SP; Mosley RT; Guo L; Underwood DJ; Arison BH; Birzin ET; Hayes EC; Mitra SW; Parmar RM; Cheng K; Wu TJ; Butler BS; Foor F; Pasternak A; Pan Y; Silva M; Freidinger RM; Smith RG; Chapman K; Schaeffer JM; Patchett AA Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10836-41. PubMed ID: 9724791 [TBL] [Abstract][Full Text] [Related]
9. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. Singh V; Brendel MD; Zacharias S; Mergler S; Jahr H; Wiedenmann B; Bretzel RG; Plöckinger U; Strowski MZ J Clin Endocrinol Metab; 2007 Feb; 92(2):673-80. PubMed ID: 17105845 [TBL] [Abstract][Full Text] [Related]
10. From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling. Guba W; Green LG; Martin RE; Roche O; Kratochwil N; Mauser H; Bissantz C; Christ A; Stahl M J Med Chem; 2007 Dec; 50(25):6295-8. PubMed ID: 18020391 [TBL] [Abstract][Full Text] [Related]
13. Nipecotic and iso-nipecotic amides as potent and selective somatostatin subtype-2 receptor agonists. Zhou C; Guo L; Morriello G; Pasternak A; Pan Y; Rohrer SP; Birzin ET; Huskey SE; Jacks T; Schleim KD; Cheng K; Schaeffer JM; Patchett AA; Yang L Bioorg Med Chem Lett; 2001 Feb; 11(3):415-7. PubMed ID: 11212124 [TBL] [Abstract][Full Text] [Related]
14. Biologic and immunologic activities and applications of somatostatin analogs. Vale W; Rivier J; Ling N; Brown M Metabolism; 1978 Sep; 27(9 Suppl 1):1391-401. PubMed ID: 210361 [No Abstract] [Full Text] [Related]
15. Selective inhibitory effect of the analog D5-F-TrP8-D-Cys14 somatostatin on the arginine induced release of insulin, growth hormone and glucagon, in normal human beings. González-Bárcena D; Mendoza F; Graef A; Medina R; Comaru-Schally AM; Schally AV Arch Invest Med (Mex); 1985; 16 Suppl 3():105-14. PubMed ID: 2878649 [No Abstract] [Full Text] [Related]
16. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Afargan M; Janson ET; Gelerman G; Rosenfeld R; Ziv O; Karpov O; Wolf A; Bracha M; Shohat D; Liapakis G; Gilon C; Hoffman A; Stephensky D; Oberg K Endocrinology; 2001 Jan; 142(1):477-86. PubMed ID: 11145612 [TBL] [Abstract][Full Text] [Related]
17. The somatostatin receptor in human pancreatic β-cells. Braun M Vitam Horm; 2014; 95():165-93. PubMed ID: 24559918 [TBL] [Abstract][Full Text] [Related]
18. Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. Yang L; Guo L; Pasternak A; Mosley R; Rohrer S; Birzin E; Foor F; Cheng K; Schaeffer J; Patchett AA J Med Chem; 1998 Jun; 41(13):2175-9. PubMed ID: 9632348 [No Abstract] [Full Text] [Related]
19. Inhibitory action of somatostatin on pancreatic alpha and beta cell function. Leblanc H; Anderson JR; Sigel MB; Yen SS J Clin Endocrinol Metab; 1975 Apr; 40(4):568-72. PubMed ID: 1092707 [TBL] [Abstract][Full Text] [Related]